Syncore Biotechnology Co Stock Current Valuation
| 4192 Stock | TWD 35.85 0.50 1.38% |
Valuation analysis of SynCore Biotechnology helps investors to measure SynCore Biotechnology's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that SynCore Biotechnology's price fluctuation is very steady at this time. Calculation of the real value of SynCore Biotechnology is based on 3 months time horizon. Increasing SynCore Biotechnology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the SynCore stock is determined by what a typical buyer is willing to pay for full or partial control of SynCore Biotechnology Co. Since SynCore Biotechnology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of SynCore Stock. However, SynCore Biotechnology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 35.85 | Real 36.84 | Hype 35.85 | Naive 35.09 |
The intrinsic value of SynCore Biotechnology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence SynCore Biotechnology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of SynCore Biotechnology Co helps investors to forecast how SynCore stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of SynCore Biotechnology more accurately as focusing exclusively on SynCore Biotechnology's fundamentals will not take into account other important factors: SynCore Biotechnology Co Company Current Valuation Analysis
SynCore Biotechnology's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current SynCore Biotechnology Current Valuation | 2.86 B |
Most of SynCore Biotechnology's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SynCore Biotechnology Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, SynCore Biotechnology Co has a Current Valuation of 2.86 B. This is 80.06% lower than that of the Healthcare sector and 38.35% lower than that of the Biotechnology industry. The current valuation for all Taiwan stocks is 82.77% higher than that of the company.
SynCore Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SynCore Biotechnology's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SynCore Biotechnology could also be used in its relative valuation, which is a method of valuing SynCore Biotechnology by comparing valuation metrics of similar companies.SynCore Biotechnology is currently under evaluation in current valuation category among its peers.
SynCore Fundamentals
| Return On Equity | -0.43 | |||
| Return On Asset | -0.16 | |||
| Operating Margin | (13.97) % | |||
| Current Valuation | 2.86 B | |||
| Shares Outstanding | 115.08 M | |||
| Shares Owned By Insiders | 66.92 % | |||
| Price To Book | 9.34 X | |||
| Price To Sales | 221.58 X | |||
| Revenue | 6.94 M | |||
| Gross Profit | 2.97 M | |||
| EBITDA | (404.13 M) | |||
| Net Income | (458.6 M) | |||
| Cash And Equivalents | 380.81 M | |||
| Cash Per Share | 4.57 X | |||
| Total Debt | 61.11 M | |||
| Debt To Equity | 9.40 % | |||
| Current Ratio | 5.04 X | |||
| Book Value Per Share | 2.87 X | |||
| Cash Flow From Operations | (229.86 M) | |||
| Earnings Per Share | (3.73) X | |||
| Number Of Employees | 65 | |||
| Beta | 1.14 | |||
| Market Capitalization | 2.88 B | |||
| Total Asset | 824.44 M | |||
| Z Score | 28.2 | |||
| Net Asset | 824.44 M |
About SynCore Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SynCore Biotechnology Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SynCore Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SynCore Biotechnology Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with SynCore Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if SynCore Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SynCore Biotechnology will appreciate offsetting losses from the drop in the long position's value.Moving together with SynCore Stock
| 0.62 | 4743 | Oneness Biotech | PairCorr |
| 0.89 | 6547 | Medigen Vaccine Biologics | PairCorr |
| 0.83 | 4174 | OBI Pharma | PairCorr |
Moving against SynCore Stock
| 0.83 | 2345 | Accton Technology Corp | PairCorr |
| 0.7 | 0050 | YuantaP shares Taiwan | PairCorr |
| 0.68 | 0057 | Fubon MSCI Taiwan | PairCorr |
| 0.66 | 3257 | Champion Microelectronic | PairCorr |
| 0.65 | 4162 | PharmaEngine | PairCorr |
The ability to find closely correlated positions to SynCore Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace SynCore Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back SynCore Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling SynCore Biotechnology Co to buy it.
The correlation of SynCore Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as SynCore Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if SynCore Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for SynCore Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for SynCore Stock Analysis
When running SynCore Biotechnology's price analysis, check to measure SynCore Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SynCore Biotechnology is operating at the current time. Most of SynCore Biotechnology's value examination focuses on studying past and present price action to predict the probability of SynCore Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SynCore Biotechnology's price. Additionally, you may evaluate how the addition of SynCore Biotechnology to your portfolios can decrease your overall portfolio volatility.